Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030222 · ClinicalTrials.gov registry record · Phase 4
Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
A Phase 4 study, sponsored by Saint Luke's Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT03030222 is a Phase 4 study that has completed, run by Saint Luke's Health System. The registered enrollment target is 65 participants.
The verdict
NCT03030222, a Phase 4 study, has completed, sponsored by Saint Luke's Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a CardioMEMs device (a wireless hemodynamic monitoring system) implanted for non-study related clinical reasons.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Empagliflozin 10 mg Tab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-07-05 |
| Est. Completion | 2020-03-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03030222
The ClinicalTrials.gov registry entry for NCT03030222 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint Luke's Health System, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03030222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03030222 about?
NCT03030222 is a clinical study titled "Empagliflozin Impact on Hemodynamics in Patients With Heart Failure". The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a Cardio...
What is the current status of trial NCT03030222?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2017-07-05. Estimated completion is 2020-03-10.
What interventions are being tested in trial NCT03030222?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Empagliflozin 10 mg Tab (DRUG).
Who is sponsoring clinical trial NCT03030222?
This trial is sponsored by Saint Luke's Health System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.